

- **Name:** Sun-Young Kong
 - **Current Position & Affiliation:**
 - Chief Scientist, Targeted Therapy Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center (NCC)
 - Faculty, Department of Laboratory Medicine, Hospital, NCC
 - Professor, Department of Cancer Biomedical Science, NCC-GCSP(Graduate School of Cancer Science and Policy)
 - **Country:** Republic of Korea
-

- **Educational Background:**

- MD, Ewha Womens University College of Medicine (1997)
- MS, Ewha Womens University Graduate School of Medicine (2001)
- PhD, Sungkyunkwan University Graduate School of Medicine (2005)

- **Professional Experience:**

- Internship & Residency, Samsung Medical Center (1997-2002)
- Clinical Fellowship, Samsung Medical Center & NCC (2002-2005)
- Faculty, Department of Laboratory Medicine, National Cancer Center (2005-Present)
- Associate Scientist, Hematologic Malignancies Branch, National Cancer Center (2005-2009)
- Senior Scientist, Hematologic Malignancies Branch, National Cancer Center (2009-2012)
- Dana-Farber Cancer Institute (2009-2011)
- Chief, Translational Epidemiology Branch, National Cancer Center (2013-2017)
- Professor, Department of System Cancer Science, Graduate School of Cancer Science & Policy (2014-Present)
- Chief, Translational Research Branch, National Cancer Center (2017)
- Chief, Flow Cytometry Unit, National Cancer Center (2017-2019)
- Chief, Department of Laboratory Medicine, National Cancer Center (2018-2021)

- **Professional Organizations:**

- Korean Society for Laboratory Medicine (2003-)
- Korean Cancer Association (2006-)
- Korean Society of Hematology (2007-)
- Korean Society of Medical Oncology (2012-)
- Korean Society for Genetic Diagnostics (2013-)
- Korea Genome Organization (2015 -)

- **Main Scientific Publications:**

- Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study: Cancers (2021)

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer: *Cancer Science* (2020)
- Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test: *Cancer Research and Treatment* (2020)
- Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer: *Cancers* (2019)
- Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women: *Cancer Science* (2019)
- Differences in attitudes toward genetic testing among the public, patients, and health-care professionals in Korea: *European journal of human genetics* (2018)
- Prognostic implications of multiplex detection of KRAS mutations in cell-free DNA from patients with pancreatic ductal adenocarcinoma: *Clinical Chemistry* (2018)
- Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers: *Cancer Research and Treatment* (2018)
- Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients: *Breast Cancer Research and Treatment* (2017)
- Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes Among Korean Breast Cancer Patients: *Cancer Research and Treatment* (2016)